WO 2016/169807 A1 - Biomarkers For Predicting Degree Of Weight Loss In Female Subjects - The Lens

Biomarkers For Predicting Degree Of Weight Loss In Female Subjects

Published: Oct 27, 2016
Earliest Priority: Apr 22 2015
Family: 7
Cited Works: 35
Cited by: 0
Cites: 10
Additional Info: Cited Works Full text Published

Abstract

A method for predicting the degree of weight loss in a female subject attainable by applying one or more dietary interventions to a subject, said method comprising; determining the level of one or more biomarkers in one or more samples obtained from the subject, wherein the biomarkers are selected from gelsolin, apolipoprotein B-100, plasma kallikrein, protein Z- dependent protease inhibitor and plasma serine protease inhibitor.

Claims

A method for predicting the degree of weight loss in a female subject attainable by applying one or more dietary interventions to a subject, said method comprising: determining the level of one or more biomarkers in one or more samples obtained from the subject, wherein the biomarkers are selected from gelsolin, apolipoprotein B-100, plasma kallikrein, protein Z-dependent protease inhibitor and plasma serine protease inhibitor.
The method according to claim 1 , wherein the method comprises determining the level of gelsolin in one or more samples.
The method according to claim 2, wherein the method further comprises determining the level of apolipoprotein B-100, plasma kallikrein, protein Z-dependent protease inhibitor or plasma serine protease inhibitor in one or more samples.
The method according to claim 3, wherein the method comprises determining the level of gelsolin, apolipoprotein B-100, plasma kallikrein, protein Z-dependent protease inhibitor and plasma serine protease inhibitor in one or more samples.
The method according to claim 4, wherein levels of each of gelsolin, apolipoprotein B-100, plasma kallikrein, protein Z-dependent protease inhibitor, and plasma serine protease inhibitor are determined, and decreased levels of apolipoprotein B-100 and plasma serine protease inhibitor and increased levels gelsolin, plasma kallikrein and protein Z-dependent protease inhibitor in the sample is indicative of a greater degree of weight loss in the subject.
The method according to any one of claims 1 to 5, wherein the one or more samples are derived from blood.
The method according to any one of claims 1 to 6, wherein the dietary intervention is a low calorie diet. The method according to claim 7, wherein the low calorie diet comprises a intake of about 600 to about 1200 kcal/day.
The method according to claim 7 or 8, wherein the low calorie diet comprises
administration of at least one diet product.
The method of any one of claims 7 to 9, wherein the low calorie diet has a duration of 6 to 12 weeks. 11. The method according to any one of claims 1 to 10, wherein the method further
comprises combining the level of the one or more biomarkers with one or more anthropometric measures and/or lifestyle characteristics of the subject.
The method according to claim 11, wherein the anthropometric measures include age and body mass index.
The method according to any one of claims 1 to 12, wherein the degree of weight loss is represented by the body mass index that a subject is predicted to attain by applying a dietary intervention.
A method for optimizing one or more dietary interventions for a female subject
comprising:
predicting the degree of weight loss attainable by the subject according to a method as defined in any one of claims 1 to 13; and
applying the dietary intervention to the subject.
A method for predicting the body mass index that a female subject would be expected to attain from a dietary intervention (BMI2), wherein the method comprises:
a. determining the level of gelsolin, apo lipoprotein B-100, plasma kallikrein, protein Z-dependent protease inhibitor and plasma serine protease inhibitor in one or more samples obtained from the subject; and
b. predicting BMI2 using formula (1): bmi2 i = cl *bmili + c2* agei - c3* gelsolin i - c4* plasma kallikrein i
- c5* protein Z-dependent protease inhibitor i + c6* apolipoprotein B-100 i +
c7* plasma serine protease inhibitor ;; wherein BMIl is the subject's body mass index before the dietary intervention and BMI2 is the subject's predicted body mass index after the dietary intervention; and wherein cl, c2, c3, c4, c5, c6 and c7 are positive integers.
A method for selecting a modification of lifestyle of a subject, the method
comprising:
a. performing a method as described in any of claims 1 to 15; and
b. selecting a suitable modification in lifestyle based upon the degree of weight loss predicted in step (a).
The method according to claim 16, wherein the modification of lifestyle in the subject comprises a dietary intervention.
The method according to claim 17, wherein the dietary intervention is as defined in any one of claims 7 to 10.
A diet product for use as part of a low calorie diet for weight loss, wherein the diet product is administered to a female subject that is predicted to attain a degree of weight loss by the method of any one of claims 1 to 15.
A diet product for use in treating obesity or an obesity-related disorder, wherein the diet product is administered to a female subject that is predicted to attain a degree of weight loss by the method of any one of claims 1 to 15.
Use of a diet product in a low calorie diet for weight loss wherein the diet product is administered to a female subject that is predicted to attain a degree of weight loss by the method of any one of claims 1 to 15.
A computer program product comprising computer implementable instructions for causing a programmable computer to perform the method of any of claims 1 to 18.
A computer program product comprising computer implementable instructions for causing a programmable computer to predict the degree of weight loss in a female subject given the levels of one or more bio markers from the user, wherein the biomarkers are selected from gelsolin, apolipoprotein B-100, plasma kallikrein, protein Z-dependent protease inhibitor and plasma serine protease inhibitor. 24. The product according to claim 23, wherein the computer program product is further given anthropometric measures and/or lifestyle characteristics from the user.
The product according to claim 24, wherein anthropometric measures include age and body mass index.
A kit for predicting the degree of weight loss attainable by a female subject following a dietary intervention, wherein said kit comprises two or more of:
a. an antibody specific for gelsolin;
b. an antibody specific for apolipoprotein B-100;
c. an antibody specific for plasma kallikrein;
d. an antibody specific for protein Z-dependent protease inhibitor; and e. an antibody specific for plasma serine protease inhibitor. kit according to claim 26 comprising
a. an antibody specific for gelsolin;
b. an antibody specific for apolipoprotein B-100;
c. an antibody specific for plasma kallikrein;
d. an antibody specific for protein Z-dependent protease inhibitor; and e. an antibody specific for plasma serine protease inhibitor.